TY  - CONF

T1  - AZD2171, an oral, highly potent VEGFR signaling inhibitor, in combination with gefitinib or paclitaxel: Results of a study in an orthotopic human lung adenocarcinoma model.

JO  - CLINICAL CANCER RESEARCH

PY  - 2005/01/01

AU  - Wu WJ

AU  - Fujitaka K

AU  - Mandal J

AU  - Imagumbai T

AU  - Ryan A

AU  - Jurgensmeier J

AU  - Fidler IJ

AU  - O'Reilly MS

AU  - Herbst RS

ED  - 

VL  - 11

IS  - 24

SP  - 9034S

EP  - 9034S

Y2  - 2024/12/26

ER  -